Alzheimer's Disease/Cognition News

The FDA has granted orphan drug designation to an investigational oral therapeutic for the treatment of Huntington’s disease, according to the manufacturer.

For individuals exposed to athletic-related head contact, glial fibrillary acidic protein may help identify those who are at risk for progressive regional brain atrophy and cognitive decline, per data from Alzheimer’s Research & Therapy.

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.

Researchers reported that HF was independently prognostic of both cardiac and cerebral microvascular dysfunction predictive of impaired cognitive function.

In a diverse cohort of Hispanic/Latino individuals, longer sleep duration was associated with lower total brain and gray matter volume, according to research published in Alzheimer’s & Dementia.

The FDA has accepted an investigational new drug application for VG-3927, an oral small molecule TREM2 agonist for the potential treatment of Alzheimer’s disease, according to the manufacturer.

PHILADELPHIA — A machine learning model was better able to predict preclinical Alzheimer’s disease from participant biomarkers as well as driving data from a year-long study, according to a speaker.

The FDA has granted 510(k) clearance to German medical technology company AIRAmed for its medical image management and processing system designed to assist physicians in early detection of Alzheimer’s disease and other dementias.

PHILADELPHIA — In order for underserved communities to successfully engage in clinical research, clear communication and multidisciplinary outreach by the medical community is necessary, according to a speaker.

PHILADELPHIA — Consideration of multiple factors among patients, families and health care providers drive the process of diagnosing preclinical or prodromal neurologic disease, which should be tailored to the individual, a speaker said.